1. In Vivo

Resilience Is Key For Medtechs Facing Provider And Payer Flux In 2018

 
• By Ashley Yeo

Medtech firms entered 2018 knowing that demands from providers and payers are increasing, the pace of business is quickening, and at the same time patients are more empowered and market access routes are more exacting than ever. Against this backdrop, PwC explains the top health industry issues for the coming year, highlights the forces that will have the most impact on the industry in 2018 and explains why manufacturers need to be nimble.

What changes should medtech companies, including those with IT applications, expect from 2018, or, put another way, how should they prepare to serve a global health care sector that is expecting "more and different" from its industry partners? PwC partner and US health services sector leader Gurpreet Singh believes that industry players need to show creativity and flexibility, but most of all resilience, to stay one step ahead of the changes – and the competition.

Speaking to In Vivo after the release of “Top Health Industry Issues of 2018,” the PwC Health Research Institute's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.